Sina Medicine Live Lesson 10 - Use precision medicine to develop the world's first innovative drug

In recent years, pharmaceutical industry policies have been introduced, consistent evaluation, China's accession to ICH, MAH implementation, drug clinical trial data verification and other accelerated industry survival of the fittest;
the reform of medical policy, the development of China's pharmaceutical industry is entering the fast track of norms.
the context of the rise of "healthy China" as a national strategy, China is undergoing a transformation from a "medical power" to a "medical power".
biopharmaceutical industry, as one of china's seven strategic emerging industries, is becoming a new engine of China's economic development.
through policy regulation, investment of supporting resources and improvement of institutional mechanism construction, China's biopharmaceutical industry has transitioned from "technological backwardness" to "following the international pace", in which the development of innovative drugs is particularly rapid.
has emerged a number of innovative biopharmaceutical companies, such as Baiji Shenzhou, Xinda Bio, Soyuan Bio, and independent research and development of innovative drugs were approved for market.
to sustain rapid growth, more top talent will be needed and the overall level of employees will be improved.
to provide innovative drug practitioners with a free and smooth exchange platform, Sina Pharmaceuticals launched a special "New Zhihui" online live knowledge sharing platform, will focus on drug research and development in the target discovery, new technology development and application, process development and verification, drug clinical trial design and other hot topics, through strategy and case sharing, directly hit the confusion in research and development production.
Tational December 22nd, the 10th lesson of "New Zhihui" hits the pound, and Dr. Green, Executive Medical Director of Soyuan Biopharmaceuticals, will share with you "the world's first innovative drug to develop precision medicine" and look forward to your participation.
Sharing Theme: Using Precision Medicine to Develop the World's First Innovative Drug 1, 2019 Global Research and Development Status Review 2, Precision Medicine Helps Innovative Drug Research and Development - "New Drug Regeneration" Mode 3, Tumor and CNS New Drug Research and Development Case Lecture under the guidance of Biomarkers Person: Dr. Green Ph.D. Soryuan Biopharmaceutical Executive Medical Director Live Time: December 22, 2020 19:30-20:30 Soryuan Biopharmaceutical Executive Medical Director Dr. Green Yuan Biopharmaceuticals, Executive Medical Director.
has been carrying out clinical work and research and development of new drugs in the field of central nervous system for 20 years, involving central neurodegenerative diseases, neuroimmune rare diseases, cerebrovascular diseases, mental diseases, and brain tumors.
Green graduated from Beijing Capital Medical University in 1994 and served as a neurology clinician for 7 years, and in 2006 received his Ph.D. in Biomedical Sciences from the University of California, Riverside, specializing in tumor signaling.
returned to China to join Johnson and Johnson (Jansen Pharmaceuticals) and Danish Lingbei company for medical research and development work, successfully led to the approval and listing of 2 new CNS drugs.
joined Soyuan Biotech in 2019 as Executive Medical Director responsible for global clinical development in the field of central nervous and neuro-tumors.
: This course is free and open, scan the QR code below to add Sina Medicine Live Assistant, get live link.
(Note: Name and Company)